TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01172509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-baclofen
Description: oral R-baclofen at 0x2, 3, 10, and 25 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-baclofen
Description: oral R-baclofen at 0x2, 3, 10, and 25 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-baclofen
Description: oral R-baclofen at 0x2, 3, 10, and 25 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: R-baclofen
Description: oral R-baclofen at 0x2, 3, 10, and 25 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: R-baclofen
Description: oral R-baclofen at 0x2, 3, 10, and 25 mg
Study: NCT03056911

Intervention type: DRUG
Intervention: Ozone
Description: Pain relief with chemonucleolysis by using ozone regard to age, sex, ASA score, and complications.
Study: NCT02648750

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bridges self-management programme
Description: The Bridges self-management programme is based on self-efficacy principles. It includes a Bridges stroke workbook consisting of stroke survivors' experiences and strategies, with space to record and reflect on personal goals and achievements, which the practitioner will work through with the participant. The practitioner will also used strategies based on key principles of self-management during interactions with patients.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Bridges self-management programme
Description: The Bridges self-management programme is based on self-efficacy principles. It includes a Bridges stroke workbook consisting of stroke survivors' experiences and strategies, with space to record and reflect on personal goals and achievements, which the practitioner will work through with the participant. The practitioner will also used strategies based on key principles of self-management during interactions with patients.
Study: NCT03501186

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Backward walking on sand
Description: the patient will be walking backwards on sand with therapist standing close to support in case of fall.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Backward walking on sand
Description: the patient will be walking backwards on sand with therapist standing close to support in case of fall.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Backward walking on sand
Description: the patient will be walking backwards on sand with therapist standing close to support in case of fall.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Backward walking on sand
Description: the patient will be walking backwards on sand with therapist standing close to support in case of fall.
Study: NCT01387919

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged fasting
Description: 48 hours of fasting
Study: NCT01013766

Intervention type: DRUG
Group type: OTHER
Intervention: GSK1362885
Description: 100mg in the AM, 100mg in the PM, 50mg BID

Intervention type: DRUG
Group type: OTHER
Intervention: GSK1362885
Description: 100mg in the PM, 100mg in the AM, 50mg BID
Study: NCT02374021

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Subjects entering trial will continue on MTX dose of at least 15mg MTX/week. At the discretion of the treating rheumatologist, may be switched to SQ route.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Subjects entering trial will continue on MTX dose of at least 15mg MTX/week. At the discretion of the treating rheumatologist, may be switched to SQ route.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfasalazine
Description: 1 gm bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: 200 mg twice daily, not to exceed 6.5mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etanercept
Description: 50 mg SC weekly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: 40 mg SQ every other week
Study: NCT04727918

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Polypectomy of diminutive colorectal polyps will be performed by CBF
Description: All polypectomy procedures will be standardized amongst the study centers. Endoscopists with a minimal experience of at least 50 CBF and CSP performed the polypectomies CBF : The CBF will be performed using a standard biopsy forceps (Gluton Life ® Life Partners). Multiple biopsies bites were taken until complete resection (as many as needed).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Polypectomy of diminutive colorectal polyps will be performed by CSP
Description: All polypectomy procedures will be standardized amongst the study centers. Endoscopists with a minimal experience of at least 50 CBF and CSP performed the polypectomies CSP : The CSB procedure will be performed using a 9 mm cold snare (Exacto ® Life Partners). One to two mm of normal surrounding mucosa will be ensnared around the base of the polyp, followed by mechanical excision without electrocautery
Study: NCT00225576

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Implementation
Description: Intervention subjects implemented electronic prescribing as part of an electronic health record implementation
Study: NCT06248346

Intervention type: DRUG
Intervention: Dexmedetomidine
Description: whether intraoperative dexmedetomidine was administered adjunct to propofol for patients undergoing surgeries under general anaesthesia
Study: NCT01144767

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer-generated advisor
Description: Weekly sessions with a computer generated advisor who offers advice, feedback and guidance on physical activity

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparison control condition
Description: Weekly/biweekly sessions with a group facilitator to receive health education and information.
Study: NCT02790580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose-dense doxorubicin/cyclophosphamide + sunitinib
Description: Doxorubicin 60mg/m2 day 1, every 2 weeks x 4 cycles Cyclophosphamide 600mg/m2 day1, every 2 weeks x 4 cycles Subcutaneous pegfilgrastim 6mg, 24-36 hours after each cycle of doxorubicin/cyclophosphamide Oral sunitinib 12.5mg daily for 7 days prior to cycle 1 ddAC (days -7 to 0) Oral sunitinib 12.5mg daily for 5 days prior to cycle 2, 3, 4 ddAC (days 10-14 of preceding cycle)~Lumpectomy or mastectomy with sentinel lymph node biopsy or axillary lymph node clearance as appropriate should be considered after completing four cycles of chemotherapy for curative intent in non-metastatic patients and for local control for patients with metastatic disease.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dose-dense doxorubicin/cyclophosphamide
Description: Doxorubicin 60mg/m2 day 1, every 2 weeks x 4 cycles Cyclophosphamide 600mg/m2 day1, every 2 weeks x 4 cycles Subcutaneous pegfilgrastim 6mg, 24-36 hours after each cycle of doxorubicin/cyclophosphamide~Lumpectomy or mastectomy with sentinel lymph node biopsy or axillary lymph node clearance as appropriate should be considered after completing four cycles of chemotherapy for curative intent in non-metastatic patients and for local control for patients with metastatic disease.
Study: NCT01211743

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic cholecystectomy
Description: Standard 4 port laparoscopic cholecystectomy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Single incision laparoscopic cholecystectomy
Description: One port placed through the umbilicus

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Single incision laparoscopic cholecystectomy
Description: One port placed through the umbilicus
Study: NCT01276431

Intervention type: DRUG
Group type: OTHER
Intervention: Buprenorphine transdermal patch
Study: NCT04017325

Intervention type: OTHER
Intervention: no intervention (post study follow up)
Description: No intervention (post study follow up)

Intervention type: OTHER
Intervention: no intervention (post study follow up)
Description: No intervention (post study follow up)
Study: NCT00736762

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GPR
Description: The subjects randomised to the GPR program will participate in posture retraining techniques of approximately forty minutes, one time a week for ten weeks.
Study: NCT00006461

Intervention type: DRUG
Group type: OTHER
Intervention: cisplatin
Description: Given IV

Intervention type: DRUG
Group type: OTHER
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: OTHER
Intervention: vincristine sulfate
Description: Given IV

Intervention type: DRUG
Group type: OTHER
Intervention: etoposide
Description: Given PO
Study: NCT03610165

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acumen HPI-enabled EV1000 screen
Description: Acumen HPI-enabled EV1000 screen.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Arterial waveform and pressures
Study: NCT03125213

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AL-3778
Description: AL-3778 tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon Alfa-2A
Description: Peginterferon Alfa-2A for subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Peginterferon Alfa-2A
Description: Peginterferon Alfa-2A for subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo to Match AL-3778 tablet
Study: NCT02802709

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SB-061
Description: delivered via intra-articular injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01088256

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoricoxib
Description: the patients get etoricoxib 90mg for 8 days. They get one pill with 90mg per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoricoxib
Description: the patients get etoricoxib 90mg for 8 days. They get one pill with 90mg per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: patients get one pill of placebo (sugar-pill) per day for 8 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: patients get one pill of placebo (sugar-pill) per day for 8 days.
Study: NCT03744325

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Hen's egg OIT
Description: Increasing doses of egg white protein administered orally
Study: NCT04547673

Intervention type: DIAGNOSTIC_TEST
Intervention: rigid nasal endoscopes
Description: The endoscope is introduced through the nasal passage to observe, in sequence, the posterior nostril, superior and posterior walls of the nasopharynx, torus tubarius, pharyngeal opening of the auditory tube, and Rosenmu¨ller recess. The imaging light mode is set to conventional WLI and subsequently switch to NBI during the procedure, and representative images are collected and preserve for further analysis. All lesions, detected by either WLI or NBI, are biopsied.

Intervention type: DIAGNOSTIC_TEST
Intervention: rigid nasal endoscopes
Description: The endoscope is introduced through the nasal passage to observe, in sequence, the posterior nostril, superior and posterior walls of the nasopharynx, torus tubarius, pharyngeal opening of the auditory tube, and Rosenmu¨ller recess. The imaging light mode is set to conventional WLI and subsequently switch to NBI during the procedure, and representative images are collected and preserve for further analysis. All lesions, detected by either WLI or NBI, are biopsied.
Study: NCT00903656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicinhydrochloride, Lapatinib
Description: Lapatinib 1250mg/d p.o. Caelyx 40 mg/m² i.v. q4w for a maximum of 6 cycles
Study: NCT04423354

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transthoracic Single-hole Assisted Laparoscopic Radical Gastrectomy for Siewert Type Ⅱ Adenocarcinoma of Esophagogastric Junction
Description: Patients diagnosed with Siewert Ⅱ adenocarcinoma of esophagogastric junction and met the inclusion criteria will be assigned to the research group and carry out transthoracic single-hole assisted laparoscopic radical gastrectomy by the fixed surgical group.The same model surgical instruments will be provided by the same instrument company.
Study: NCT02244996

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lycium Barbarum
Description: Traditional Chinese Herbs

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02038920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Description: Vedolizumab IV injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Description: Vedolizumab IV injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Description: Vedolizumab IV injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vedolizumab placebo
Description: Vedolizumab placebo-matching IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vedolizumab placebo
Description: Vedolizumab placebo-matching IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vedolizumab placebo
Description: Vedolizumab placebo-matching IV infusion
Study: NCT01798277

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter Ablation
Description: Catheter ablation of ventricular tachycardia will employ three-dimensional mapping Fast Anatomical Mapping or CARTOSOUND technology (Biosense Webster Inc.), and the Thermocool Navistar catheter (Biosense Webster Inc.).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medical therapy (sotalol or amiodarone)
Description: Patients will be tiered to one of two possible antiarrhythmic drugs (sotalol or amiodarone).
Study: NCT04829929

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Omega™LAA Occluder implantation
Description: Left Atrial Appendage closure for patients with non-valvular atrial fibrillation (NVAF) and high bleeding risk by Omega™LAA Occluder using Omega™ Delivery System
Study: NCT02729623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kite Systems cannaHALER cannabis Inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kite Systems cannaHALER cannabis Inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kite Systems cannaHALER cannabis Inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kite Systems cannaHALER cannabis Inhaler.
Study: NCT01998009

Intervention type: OTHER
Group type: OTHER
Intervention: fecal occult blood tests
Study: NCT02561533

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BRAF detection on fine needle aspiration biopsy (FNAB)
Study: NCT00724308

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telephone Care Coordination
Description: The telephone care coordination program involves the following steps: (1) brief counseling and referral from a mental health provider; (2) prescribing and mailing of smoking cessation medications; (3) proactive multi-call counseling from TeleQuit MH study counselors; and (4) follow-up at 2 and 6 months to check the patient's smoking status.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telephone Care Coordination with state Quitline
Description: The telephone care coordination program involves the following steps: (1) brief counseling and referral from a mental health provider; (2) prescribing and mailing of smoking cessation medications; (3) proactive multi-call counseling from the patient's state Quitline; and (4) follow-up at 2 and 6 months to check the patient's smoking status.
Study: NCT03459014

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stimulus rich VE
Description: Participants will walk in the Lokomat with the VR for 21 minutes. After every 7 minutes, the speed of the OF will change (2 times the comfortable walking speed, equally to the comfortable walking speed, and 0.5 times the comfortable walking speed).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stimulus poor VE
Description: Participants will walk in the Lokomat with the VR for 21 minutes. After every 7 minutes, the speed of the OF will change (2 times the comfortable walking speed, equally to the comfortable walking speed, and 0.5 times the comfortable walking speed).
Study: NCT04530331

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition education
Description: Dietitians visited the worksites of the intervention group once a week to deliver a nutrition education session and provide dietary advice for each participant.
Study: NCT03701867

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Metabolic Flexibility Tests
Description: Energy Metabolism, Oxygenation, Body Composition, Blood Samples
Study: NCT01912456

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low-volume C1-esterase inhibitor

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low-volume C1-esterase inhibitor

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Higher-volume C1-esterase inhibitor

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Higher-volume C1-esterase inhibitor

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low-volume placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low-volume placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Higher-volume placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Higher-volume placebo
Study: NCT01340196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tenofovir/BI 201335
Description: tenofovir medium dose once daily (qd) for first 15 days; BI 201335 medium dose twice daily (bid) on days 8 through 22 with last dose on morning of day 22
Study: NCT00185679

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS System
Description: The CliniMACS System is a cell selection device consisting of the following components:~1. Computer-controlled instrument;~2. Sterile disposable tubing set (PVC tubing, filters and bags connected to two separation columns containing an iron/plastic matrix)~3. Anti-CD34 antibody reagent (murine monoclonal antibody chemically coupled to a magnetic particle)~4. Wash buffer
Study: NCT00823056

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: probiotics
Description: placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: probiotics
Description: 0,53 ml MCT oil containing BB12 and TH4 in daily dosage in 9 months
Study: NCT00006461

Intervention type: PROCEDURE
Group type: OTHER
Intervention: therapeutic conventional surgery
Description: Undergo surgery

Intervention type: RADIATION
Group type: OTHER
Intervention: 3-dimensional conformal radiation therapy
Description: Undergo 3-dimensional conformal radiation therapy
Study: NCT02433418

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tubal flushing by Urografin®
Description: Women will have tubal flushing through HSG using water soluble media (Urographin ®)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac
Description: Women will receive oral diclofenac 50 mg (voltaren ®) 1 hour before hysterosalpingography
Study: NCT02200406

Intervention type: DRUG
Group type: OTHER
Intervention: Desvenlafaxine
Description: All subjects will receive 50 mg of the medication during week 1 and 2, then 50-100 mg (based on the psychiatrist judgment) for the following 6 weeks. Subjects who experience significant adverse reactions with the 100mg dose during weeks 2 to 4 could return to the lower dose of 50 mg if judged clinically appropriate by the study psychiatrist.
Study: NCT01528332

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pain Relief Patch
Description: The Pain Relief Patch is a non CE-marked device that is worn on the painful area of the back, where it shines light (453 ± 7 nm, maximum 42 ± 6 mW/cm2 and average 20 ± 1 mW/cm²). It will be used 5 times over 14 days for 30 minutes each time.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control PRP device
Description: The Control PRP device is also a non CE-marked device. It is similar in appearance to the active Pain Relief Patch, except that it shines light of a different wavelength(531 ± 7 nm, maximum 0.4 ± 0.1 mW/cm² and average 0.2 ± 0.05 mW/cm²) for just 5 seconds before it turns off. Participants in the control arm will be treated with the control PRP device 5 times over 14 days for 30 minutes each time.
Study: NCT00600080

Intervention type: DEVICE
Group type: OTHER
Intervention: etafilcon A
Description: contact lens worn daily for one week (first or second week depending on arm)

Intervention type: DEVICE
Group type: OTHER
Intervention: etafilcon A
Description: contact lens worn daily for one week (first or second week depending on arm)

Intervention type: DEVICE
Group type: OTHER
Intervention: nelfilcon A
Description: Contact lens worn daily for one week (first or second week depending on arm)

Intervention type: DEVICE
Group type: OTHER
Intervention: nelfilcon A
Description: Contact lens worn daily for one week (first or second week depending on arm)
Study: NCT03338192

Intervention type: OTHER
Intervention: QST
Description: All participants will undergo quantitative sensory testing for assessment of endogenous pain modulation using painful heat, mechanical, and cold stimuli in a laboratory session lasting approximately 1 hour.

Intervention type: OTHER
Intervention: QST
Description: All participants will undergo quantitative sensory testing for assessment of endogenous pain modulation using painful heat, mechanical, and cold stimuli in a laboratory session lasting approximately 1 hour.
Study: NCT03621475

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Novel restraint
Description: Use of a novel arm restraint

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Novel restraint
Description: Use of a novel arm restraint
Study: NCT01596010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2 mg estradiol / 1 mg norethisterone acetate (NETA)
Description: A single dose of one tablet under fasting conditions separated by a wash-out period of 2 weeks (+0-2 days) between dosing visits. Administered orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2 mg estradiol / 1 mg norethisterone acetate (NETA)
Description: A single dose of one tablet under fasting conditions separated by a wash-out period of 2 weeks (+0-2 days) between dosing visits. Administered orally.
Study: NCT03873077

Intervention type: PROCEDURE
Group type: OTHER
Intervention: local infiltration analgesia
Description: 10 mL ropivacaine 7.5 mg/mL and 10 mL lidocaine 10 mg/mL
Study: NCT04102306

Intervention type: OTHER
Intervention: reliability and validity construct of the TMIQ
Description: comparison of the TMIQ to the gold-standard questionnaire (KVIQ) and test-retest

Intervention type: OTHER
Intervention: reliability and validity construct of the TMIQ
Description: comparison of the TMIQ to the gold-standard questionnaire (KVIQ) and test-retest